Education
About Us
Working with TipRanks
Follow Us
uniQure N.V. (QURE)
NASDAQ:QURE
QURE Stock Chart & Stats
$27.96
-$1.39(-7.88%)
At close: 4:00 PM EST
$27.96
-$1.39(-7.88%)
Day’s Range― - ―
52-Week Range$5.86 - $71.50
Previous CloseN/A
Volume1.49M
Average Volume (3M)3.82M
Market Cap
$1.72B
Enterprise Value$3.25B
Total Cash (Recent Filing)$694.25M
Total Debt (Recent Filing)$66.16M
Price to Earnings (P/E)―
Beta1.15
Next Earnings
Mar 02, 2026EPS Estimate
-0.91Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-1.38
Shares Outstanding61,603,770
10 Day Avg. Volume2,792,720
30 Day Avg. Volume3,816,279
Financial Highlights & Ratios
PEG Ratio0.15
Price to Book (P/B)-127.24
Price to Sales (P/S)31.68
P/FCF Ratio-4.62
Enterprise Value/Market Cap1.89
Enterprise Value/Revenue206.53
Enterprise Value/Gross Profit234.35
Enterprise Value/Ebitda-22.24
Forecast
1Y Price Target
$62.60Price Target Upside123.89% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering12
EPS Forecast (FY)-3.84
Revenue Forecast (FY)$16.28M
Bulls Say, Bears Say
Bulls Say
Financial PositionWith $694.2 million in cash extending runway into 2029 and multiple regulatory and data catalysts ahead, uniQure remains well positioned to reestablish the U.S. path for AMT-130.
Gene Therapy AdvancementsUniQure delivered a pivotal quarter marked by historic 3-year AMT-130 gene therapy data in Huntington’s disease.
Regulatory PathwayThere is strong alignment with the FDA, and QURE has received breakthrough therapy designation for AMT-130's earlier data.
Bears Say
Clinical Trial SetbacksThe company has paused enrollment in the Phase I/II EPISOD1 study of AMT-162 due to a dose-limiting toxicity reported in one patient.
FDA Approval ChallengesQURE unexpectedly and unfortunately reported that it appears the FDA no longer aligns on the previously suggested path to accelerated approval.
Regulatory UncertaintyNear-term regulatory uncertainty tempers momentum, but data strength and platform depth reaffirm long-term conviction.
uniQure News
QURE FAQ
What was uniQure N.V.’s price range in the past 12 months?
uniQure N.V. lowest stock price was $5.86 and its highest was $71.50 in the past 12 months.
What is uniQure N.V.’s market cap?
uniQure N.V.’s market cap is $1.72B.
When is uniQure N.V.’s upcoming earnings report date?
uniQure N.V.’s upcoming earnings report date is Mar 02, 2026 which is in 95 days.
How were uniQure N.V.’s earnings last quarter?
uniQure N.V. released its earnings results on Nov 10, 2025. The company reported -$1.38 earnings per share for the quarter, missing the consensus estimate of -$0.903 by -$0.477.
Is uniQure N.V. overvalued?
According to Wall Street analysts uniQure N.V.’s price is currently Undervalued.
Does uniQure N.V. pay dividends?
uniQure N.V. does not currently pay dividends.
What is uniQure N.V.’s EPS estimate?
uniQure N.V.’s EPS estimate is -0.91.
How many shares outstanding does uniQure N.V. have?
uniQure N.V. has 61,603,770 shares outstanding.
What happened to uniQure N.V.’s price movement after its last earnings report?
uniQure N.V. reported an EPS of -$1.38 in its last earnings report, missing expectations of -$0.903. Following the earnings report the stock price went down -5.901%.
Which hedge fund is a major shareholder of uniQure N.V.?
Currently, no hedge funds are holding shares in QURE
uniQure Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$62.60 (123.89% Upside)
$62.60 (123.89% Upside)
Blogger Sentiment
Bullish
QURE Sentiment 100%
Sector Average 69%
Sector Average 69%
Hedge Fund Trend
Increased
By 591.1K Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Very Negative
Last 7 Days ▼ 2.1%
Last 30 Days ▼ 2.9%
Last 30 Days ▼ 2.9%
News Sentiment
Neutral
Bullish news 59%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Positive
20 days / 200 days
Momentum
380.62%
12-Months-Change
Fundamentals
Return on Equity
-165.27%
Trailing 12-Months
Asset Growth
37.56%
Trailing 12-Months
Company Description
uniQure N.V.
uniQure N.V., a gene therapy company, engages in the development of treatments for patients suffering from genetic and other devastating diseases. Its lead program is Etranacogene dezaparvovec (AMT-061), which is in Phase III HOPE-B pivotal trial for the treatment of hemophilia B. The company also engages in developing AMT-130, a gene therapy that is in Phase I/II clinical study for the treatment of Huntington's disease; AMT-060, which is in Phase I/II clinical trial for the treatment of hemophilia B; AMT-210, a product candidate for the treatment of Parkinson's disease; AMT-260 for temporal lobe epilepsy; AMT-240, a preclinical product candidate for the treatment of autosomal dominant Alzheimer's disease; and AMT-161 for the treatment of amyotrophic lateral sclerosis. uniQure N.V. was founded in 1998 and is headquartered in Amsterdam, the Netherlands.
QURE Earnings Call
Q3 2025
0:00 / 0:00
Earnings Call Sentiment|Neutral
The earnings call showcased significant advancements in uniQure's therapeutic pipeline, particularly for Huntington's disease and epilepsy, despite regulatory challenges and increased operational costs. The financial position remains strong, supporting future operations. However, setbacks with the FDA's stance on AMT-130 and the pause in the AMT-162 program posed challenges.View all QURE earnings summariesQURE Stock 12 Month Forecast
Average Price Target
$62.60
▲(123.89% Upside)
Technical Analysis
Rocket Pharmaceuticals
―
Spyre Therapeutics
―
Intellia Therapeutics
―
CureVac
―
Day One Biopharmaceuticals
―
Ownership Overview
2.21% Insiders
10.50% Mutual Funds
7.39% Other Institutional Investors
74.93% Public Companies and Individual Investors